药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Sultopride
The risk or severity of QTc prolongation can be increased when Sultopride is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Sitafloxacin
The risk or severity of QTc prolongation can be increased when Sitafloxacin is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Oxatomide
The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Abexinostat
The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Mizolastine
The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Ricolinostat
The risk or severity of QTc prolongation can be increased when Ricolinostat is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Simendan
The risk or severity of QTc prolongation can be increased when Simendan is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
CUDC-101
The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Entinostat
The risk or severity of QTc prolongation can be increased when Entinostat is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Mocetinostat
The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Amifampridine
The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Delamanid
The risk or severity of QTc prolongation can be increased when Delamanid is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Benidipine
The risk or severity of QTc prolongation can be increased when Benidipine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Melperone
The risk or severity of QTc prolongation can be increased when Melperone is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Butriptyline
The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Eperisone
The risk or severity of QTc prolongation can be increased when Eperisone is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Fendiline
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Bedaquiline
The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Antazoline
The risk or severity of QTc prolongation can be increased when Antazoline is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Nilvadipine
The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Berotralstat.